Optometry Times Staff Reports

According to a VSP Vision Care news release, 71% say they experience performance impacts due to screen-related visual discomfort, equating to nearly one full workday of lost productivity each week.

Uveitis is a leading cause of blindness and accounts for an estimated 30,000 new cases of legal blindness annually in the US.

The monthly multifocal toric lens with novel water gradient material targets presbyopic patients with astigmatism and is available to eye care professionals nationwide.

ACP says the label “provider” blurs clinical roles, commercializes care, and erodes trust—urging words that protect medical ethics and relationships.

The study evaluated the company’s Defocus Incorporated Multiple Segments Triple Enhanced Design (DIMS TED) myopia control lenses in children aged 4–12 with progressive myopia.

The report estimates the industry’s total value at $69.5 billion.

Seventeen established and emerging eye care professionals from the United States and Canada were named as 2026 Visionaries.

The prospective observational study is being conducted across 18 countries.

The study included 144 patients with glaucoma or ocular hypertension who underwent 24-hour IOP monitoring between October 2023 and April 2024.

The lenses are commercially available in Canada as of February 2, 2026.

Nominations for the 2023 awards will close July 31, 2023.

The National Keratoconus Foundation has named NASCAR driver Joey Gase as Ambassador.

The annual conference will take place September 6-9 at the Renaissance Schaumburg Convention Center in Schaumburg, IL.

The organization now has chapters in Boston, San Antonio, New York, and Los Angeles.

Latinos En Optometry, also known as LEO, is launching and wants you to join their community as they expand membership, sponsorship, events, and engagement in the year ahead.

Kicking off AMD Awareness Month, give us your thoughts!

Essence Johnson, OD, FAAO, Dipl ABO, has been appointed as the first Black EyeCare Perspective executive director.

The positive 3-month efficacy and safety results from Azura Ophthalmic's Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD) met its co-primary endpoints.

This acquisition for Alcon means a growing ophthalmic portfolio of commercial products and development pipeline.

In honor of World Sight Day, optometrists and ophthalmologists reflect on what today means to them.

The event is part of the organization's pipeline for Black students into optometry.

Vizient, Inc., designates NYU Langone as number 1 for patient care.

This latest approval for Beovu (brolucizumab) 6 mg is the second indication granted by the EC, as it was first approved in 2020 for the treatment of AMD.

An exciting line-up of speakers and panelists is promised for the main-stage destination at VEE 2022.

Approved by the FDA last October, XIPERE (triamcinolone acetonide injectable suspension) was approved by the FDA last October as the first and only therapy for treating macular edema associated with uveitis.